Current clinical research status and future treatment directions for liver cirrhosis combined with portal vein thrombosis

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 10

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

Tables (1-1)

Sum=4

Oct 27, 2025 (publication date) through Oct 27, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Oct 27, 2025; 17(10): 109745
Published online Oct 27, 2025. doi: 10.4254/wjh.v17.i10.109745

Table 1 Recanalization ratio and prognosis of patients receiving anticoagulants, n (%)

The recanalization rate of edoxaban is high compared with that of other anticoagulants, whereas adverse effects (mainly bleeding) are relatively low.

Citation: He WL, Yan S, Lu JJ, Chen L, Wu JZ. Current clinical research status and future treatment directions for liver cirrhosis combined with portal vein thrombosis. World J Hepatol 2025; 17(10): 109745
URL: https://www.wjgnet.com/1948-5182/full/v17/i10/109745.htm
DOI: https://dx.doi.org/10.4254/wjh.v17.i10.109745